Causes and consequences of lipoprotein(a) abnormalities in kidney disease

[1]  F. Kronenberg,et al.  The mysterious lipoprotein(a) is still good for a surprise. , 2013, The lancet. Diabetes & endocrinology.

[2]  B. Nordestgaard,et al.  Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study. , 2013, The lancet. Diabetes & endocrinology.

[3]  F. Kronenberg,et al.  Lipoprotein(a): resurrected by genetics , 2013, Journal of internal medicine.

[4]  P. Talmud,et al.  Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. , 2010, Journal of the American College of Cardiology.

[5]  P. Ridker,et al.  Lipoprotein(a) and risk of type 2 diabetes. , 2010, Clinical chemistry.

[6]  J. Danesh,et al.  Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. , 2010, Journal of the American College of Cardiology.

[7]  Stephen Kaptoge,et al.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. , 2009, JAMA.

[8]  J. Witztum,et al.  The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity , 2008, Current opinion in lipidology.

[9]  F. Kronenberg,et al.  Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular Outcomes: Prospective Results From the Bruneck Study , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[10]  F. Kronenberg,et al.  In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. , 2007, Kidney international.

[11]  F. Kronenberg,et al.  Lipoprotein metabolism and lipid management in chronic kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.

[12]  F. Kronenberg,et al.  Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. , 2006, Journal of the American College of Cardiology.

[13]  N. Powe,et al.  High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. , 2005, Journal of the American Society of Nephrology : JASN.

[14]  F. Kronenberg,et al.  The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome. , 2004, Kidney international.

[15]  E. Boerwinkle,et al.  Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups , 1991, Human Genetics.

[16]  F. Kronenberg,et al.  Apolipoprotein(a) isoform-specific changes of lipoprotein(a) after kidney transplantation , 2003, European Journal of Human Genetics.

[17]  N. Powe,et al.  Small Apolipoprotein(a) Size Predicts Mortality in End-Stage Renal Disease: The CHOICE Study , 2002, Circulation.

[18]  F. Kronenberg,et al.  Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. , 2000, Journal of the American Society of Nephrology : JASN.

[19]  F. Kronenberg,et al.  Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up. , 1999, Atherosclerosis.

[20]  F. Kronenberg,et al.  The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. , 1999, Journal of the American Society of Nephrology : JASN.

[21]  C. Wanner,et al.  Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. , 1999, Kidney international.

[22]  T. Rabelink,et al.  Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. , 1998, Journal of the American Society of Nephrology : JASN.

[23]  P. Stenvinkel,et al.  Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. , 1998, Kidney international.

[24]  F. Kronenberg,et al.  Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation. , 1997, Journal of lipid research.

[25]  H. Hobbs,et al.  Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. , 1996, The Journal of clinical investigation.

[26]  F. Kronenberg,et al.  Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[27]  K. Kostner,et al.  Urinary excretion of apo(a) fragments. Role in apo(a) catabolism. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[28]  F. Kronenberg,et al.  Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. , 1995, Journal of the American Society of Nephrology : JASN.

[29]  F. Kronenberg,et al.  Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[30]  D. Rader,et al.  Elevated Plasma Lipoprotein(a) in Patients with the Nephrotic Syndrome , 1993, Annals of Internal Medicine.

[31]  F. Kronenberg,et al.  Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). , 1993, The Journal of clinical investigation.

[32]  E. Boerwinkle,et al.  Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[33]  R. Heyka,et al.  Lipoprotein(a) Is an Independent Risk Factor for Cardiovascular Disease in Hemodialysis Patients , 1992, Circulation.

[34]  G. Utermann,et al.  Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. , 1987, The Journal of clinical investigation.